A Phase 3 interventional study of Travatan in Glaucoma, Open-angle and Ocular Hypertension, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-10-07.
Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 6th largest by enrollment of the 45 interventional ones that give a count, is the only one that started in 2006, is one of 16 in phase 3, and was the 1st registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Jonathon Myers · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 45+
By country, each count listing its studies:
Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 502 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 135 across the 45 interventional studies. Of the 43 that completed or were terminated, 23 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 46 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
126 studies in Glaucoma, Open-Angle by Alcon: 1 open now, 1 under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 17th largest by enrollment of the 112 interventional ones that give a count, is one of 6 that started in 2006, is one of 43 in phase 3, and was the 7th registered.
Alcon’s Glaucoma, Open-Angle studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Alcon’s 126 in Glaucoma, Open-Angle:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.
Adult patients of any race and either sex with chronic angle-closure glaucoma.
Travoprost (0.004%)
Drug: Travatan
Travoprost (0.004%) 1 drop each eye once daily
Mean Intraocular Pressure
Mean IOP for the patient's worse eye at baseline was used in the secondary endpoint analysis. 2 consecutive IOP measurements for each eye were taken. If the 2 measurements for the same eye differ by 4 mmHg or less, the average of the measurements would be considered as the mean IOP for that eye. If the 2 measurements for the same eye differ by more than 4 mmHg, then a third measurement was to be taken. All IOP measurements were performed with a Goldmann applanation tonometer.
Time frame: At 5 years.
Patients were recruited in ophthalmic clinics, academic and civil hospitals from September 24, 2002. Last patient completed the study on March 23, 2009.
| Milestone | Travatan |
|---|---|
| Started | 502 |
| Completed | 367 |
| Not completed | 135 |
Mean IOP for the patient's worse eye at baseline was used in the secondary endpoint analysis. 2 consecutive IOP measurements for each eye were taken. If the 2 measurements for the same eye differ by 4 mmHg or less, the average of the measurements would be considered as the mean IOP for that eye. If the 2 measurements for the same eye differ by more than 4 mmHg, then a third measurement was to be taken. All IOP measurements were performed with a Goldmann applanation tonometer.
| millimeters mercury (mm Hg) | Travatan |
|---|---|
| Mean Intraocular Pressure | 16.5 ± 2.6 |
Collected over Baseline to 5 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Travatan | — | 99/502 (19.7%) | 304/502 (60.6%) |
| Event | Travatan |
|---|---|
| InjuryInjury, poisoning and procedural complications | 8/502 |
| PneumoniaInfections and infestations | 4/502 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 4/502 |
| Myocardial infarctionCardiac disorders | 3/502 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/502 |
| Cerebrovascular accidentNervous system disorders | 3/502 |
| CholecystectomySurgical and medical procedures | 3/502 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/502 |
| Cardio-respiratory arrestCardiac disorders | 2/502 |
| Respiratory tract infectionInfections and infestations | 2/502 |
| Event | Travatan |
|---|---|
| Iris hyperpigmentationEye disorders | 148/502 |
| CataractEye disorders | 147/502 |
| HypertensionVascular disorders | 83/502 |
| Visual acuity reducedEye disorders | 55/502 |
| Ocular hyperemiaEye disorders | 50/502 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 38/502 |
| Diabetes mellitusMetabolism and nutrition disorders | 26/502 |
| InjuryInjury, poisoning and procedural complications | 25/502 |
| Dry eyeEye disorders | 25/502 |
| Age, Categorical(Participants) | Travatan |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 237 |
| >=65 years | 265 |
| Sex: Female, Male(Participants) | Travatan |
|---|---|
| Female | 281 |
| Male | 221 |
The record gives a start of Jan 2006 and a primary completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Travoprost